Glycoprotein IIB/IIIA inhibitors

Thus, the volume of distribution of the central compartment in which peptides and proteins initially distribute after intravenous administration is typically 3 to 8 L, approximately equal to slightly higher than the plasma volume [19] (approximate body water volumes for a 70-kg person interstitial 12 L, intracellular 27 L, intravascular 3 L) [34]. The total volume of distribution (V ) is frequently 14 to 20 L, not more than twice the initial volume of distribution (Vc) [13, 28]. This distribution pattern has, for example, been described for the somatostatin analog octreotid (Vc 5.2-10.2 L, VIIIa inhibitor eptifibatide (Vc9.2 L) [35-37].Active tissue uptake and binding to intra- and extravascular proteins, however, can substantially increase the volume of distribution of peptide and protein drugs, as, for example, observed with atrial natriuretic peptide (ANP) [38]. 

Platelet glycoprotein IIB-IIIA inhibitors are used as adjunct to thrombolysis, angioplasty or stenting. Several studies have shown favorable outcomes in a selected group of patients (Eckert et al, 2005 Lee et al., 2002 Qureshi et al., 2006). 

GLYCOPROTEIN IIB-IIIA INHIBITORS [SED-15, 4 SEDA-31, 565 SEDA-32, 638 SEDA-33, 720]... 

---